Kestra Medical Technologies (NASDAQ:KMTS) Stock: Insider Traci Umberger Sells 30,000 Shares

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Traci Umberger sold 30,000 shares of the stock in a transaction dated Tuesday, October 27th. The stock was sold at an average price of $30.03, for a total transaction of $900,900.00. Following the sale, the insider owned 195,825 shares of the company’s stock, valued at $5,880,624.75. This trade represents a 13.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Kestra Medical Technologies Stock Performance

Shares of KMTS stock opened at $29.69 on Friday. The stock has a market capitalization of $1.77 billion, a PE ratio of -11.12 and a beta of 0.51. Kestra Medical Technologies, Ltd. has a 52-week low of $17.34 and a 52-week high of $31.06. The stock’s 50-day moving average price is $26.69 and its 200 day moving average price is $23.82. The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.33.

Kestra Medical Technologies (NASDAQ:KMTS) last posted its quarterly earnings data on Monday, September 14th. The company reported ($0.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.14). Kestra Medical Technologies had a negative return on equity of 63.83% and a negative net margin of 140.43%. The company had revenue of $30.97 million for the quarter. As a group, equities research analysts forecast that Kestra Medical Technologies, Ltd. will post -2.45 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Piper Sandler restated an “overweight” rating on shares of Kestra Medical Technologies in a research note on Tuesday, September 15th. BTIG Research reiterated a “buy” rating and issued a $32.00 price objective on shares of Kestra Medical Technologies in a research report on Tuesday, September 15th. JPMorgan Chase & Co. began coverage on shares of Kestra Medical Technologies in a research note on Monday, August 10th. They issued an “overweight” rating and a $30.00 price objective on the stock. Wolfe Research set a $30.00 price objective on shares of Kestra Medical Technologies in a research report on Wednesday, July 15th. Finally, Weiss Ratings upgraded shares of Kestra Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, September 16th. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $29.00.

Institutional Investors Weigh In On Kestra Medical Technologies

Several institutional investors have recently made changes to their positions in the stock. Sterling Capital Management LLC boosted its stake in shares of Kestra Medical Technologies by 834.0% during the 3rd quarter. Sterling Capital Management LLC now owns 878 shares of the company’s stock worth $25,000 after acquiring an additional 784 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Kestra Medical Technologies by 6.6% in the 1st quarter. The Manufacturers Life Insurance Company now owns 92,515 shares of the company’s stock worth $1,844,000 after acquiring an additional 5,731 shares during the period. California State Teachers Retirement System grew its holdings in shares of Kestra Medical Technologies by 39.2% in the 1st quarter. California State Teachers Retirement System now owns 27,835 shares of the company’s stock worth $555,000 after acquiring an additional 7,844 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new position in Kestra Medical Technologies in the 3rd quarter valued at approximately $353,000. Finally, Quantinno Capital Management LP purchased a new position in Kestra Medical Technologies in the 1st quarter valued at approximately $431,000.

Kestra Medical Technologies News Roundup

Here are the key news stories impacting Kestra Medical Technologies this week:

• Positive Sentiment: Kestra will participate in upcoming investor conferences, which could improve visibility for its wearable cardiac-monitoring and defibrillation platform and give management an opportunity to discuss growth plans. Kestra Medical Technologies to Participate in Upcoming Investor Conferences
• Neutral Sentiment: Analyst sentiment remains generally constructive, with five Buy ratings, two Holds and one Sell rating. Evercore initiated coverage with an Outperform rating and a $34 price target, while the reported average target is $29. However, the company remains unprofitable, and its latest quarterly loss exceeded consensus expectations.
• Negative Sentiment: Insider selling is the clearest near-term negative catalyst. CFO Vaseem Mahboob sold 79,500 shares across October 27–29 for approximately $2.41 million, reducing his direct holdings to 60,609 shares. Director Traci Umberger separately sold 30,000 shares for about $900,900. The transactions may raise concerns about insider confidence or encourage profit-taking after KMTS’s strong advance. Kestra Medical Technologies Insider Selling
• Negative Sentiment: Fundamentals remain a risk: Kestra reported a quarterly loss of $0.75 per share versus the expected $0.61 loss, with a negative net margin and analysts projecting a full-year loss of approximately $2.45 per share.

Kestra Medical Technologies Company Profile

Kestra Medical Technologies, Inc is a medical technology company focused on developing and commercializing wearable solutions for patients at risk of sudden cardiac arrest. Its primary product is the ASSURE wearable cardioverter defibrillator, a wearable device designed to continuously monitor a patient’s heart rhythm and deliver a therapeutic shock when clinically necessary.

The company’s platform combines cardiac monitoring, arrhythmia detection and defibrillation capabilities in a wearable system intended for use outside the hospital.